304 related articles for article (PubMed ID: 25562772)
1. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
3. Health care costs among renal cancer patients using pazopanib and sunitinib.
Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
[TBL] [Abstract][Full Text] [Related]
6. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
7. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy.
Capri S; Porta C; Condorelli C; Premoli E; Khare A; Kalra M; Modi N; Ratto B
J Med Econ; 2020 Dec; 23(12):1579-1587. PubMed ID: 33079593
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.
Benedict A; Ramaswamy K; Sandin R
J Manag Care Spec Pharm; 2015 Sep; 21(9):834-40. PubMed ID: 26308230
[TBL] [Abstract][Full Text] [Related]
10. Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib.
MacLean EA; Sandin R; Mardekian J
J Manag Care Spec Pharm; 2015 Sep; 21(9):841-3. PubMed ID: 26308231
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
[TBL] [Abstract][Full Text] [Related]
15. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.
Amdahl J; Diaz J; Park J; Nakhaipour HR; Delea TE
Curr Oncol; 2016 Aug; 23(4):e340-54. PubMed ID: 27536183
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]